Cargando…

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates

Detalles Bibliográficos
Autores principales:	Polak, Sebastian, Pugsley, Michael K., Stockbridge, Norman, Garnett, Christine, Wiśniowska, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Meeting Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476985/ https://www.ncbi.nlm.nih.gov/pubmed/25940083 http://dx.doi.org/10.1208/s12248-015-9773-1

Ejemplares similares

The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation
por: Wiśniowska, Barbara, et al.
Publicado: (2016)

The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk
por: Thind, Munveer, et al.
Publicado: (2020)

Proarrhythmia Induced by Propafenone: What is the Mechanism?
por: Femenia, Francisco, et al.
Publicado: (2010)

Transgenic Rabbit Models in Proarrhythmia Research
por: Baczkó, István, et al.
Publicado: (2020)

Proarrhythmia and Oncotherapy: So Much To Be Done!
por: Kovacs, Richard J.
Publicado: (2021)

Assessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias
por: Koike, Hideki, et al.
Publicado: (2016)

Open-access database of literature derived drug-related Torsade de Pointes cases
por: Krumpholz, Laura, et al.
Publicado: (2022)

Correction to: Open-access database of literature derived drug-related Torsade de Pointes cases
por: Krumpholz, Laura, et al.
Publicado: (2022)

General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
por: Li, Zhihua, et al.
Publicado: (2019)

Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach
por: Li, Zhihua, et al.
Publicado: (2019)

Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations
por: Tylutki, Zofia, et al.
Publicado: (2016)

Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials
por: Wiśniowska, Barbara, et al.
Publicado: (2016)

Proarrhythmia in a Patient With Heart Failure on Therapy With Amiodarone
por: Semerdzhieva, Niya E, et al.
Publicado: (2021)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
por: Uddin, Muhammad Erfan, et al.
Publicado: (2022)

Automated Algorithm for J-T(peak) and T(peak)-T(end) Assessment of Drug-Induced Proarrhythmia Risk
por: Johannesen, Lars, et al.
Publicado: (2016)

Artificial Intelligence That Predicts Sensitizing Potential of Cosmetic Ingredients with Accuracy Comparable to Animal and In Vitro Tests—How Does the Infotechnomics Compare to Other “Omics” in the Cosmetics Safety Assessment?
por: Kalicińska, Jadwiga, et al.
Publicado: (2023)

Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)
por: Strauss, David G., et al.
Publicado: (2021)

Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating
por: Wiśniowska, Barbara, et al.
Publicado: (2022)

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes
por: Malik, Marek, et al.
Publicado: (2018)

Errors of Fixed QT Heart Rate Corrections Used in the Assessment of Drug-Induced QTc Changes
por: Hnatkova, Katerina, et al.
Publicado: (2019)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models
por: Kopańska, Karolina, et al.
Publicado: (2023)

Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia
por: Ezeani, Martin, et al.
Publicado: (2017)

Corrigendum: Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Tox-Database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition
por: Polak, Sebastian, et al.
Publicado: (2012)

Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction
por: Trovato, Cristian, et al.
Publicado: (2022)

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018)

Humans Vary, So Cardiac Models Should Account for That Too!
por: Wiśniowska, Barbara, et al.
Publicado: (2017)

The open-access dataset for insilico cardiotoxicity prediction system
por: Polak, Sebastian, et al.
Publicado: (2011)

Digital drug discovery
por: Goldman, Michael A
Publicado: (2005)

Aging and drug discovery
por: Bakula, Daniela, et al.
Publicado: (2018)

Right ventricular lead proarrhythmia: A novel intervention for an under-recognized phenomenon
por: Hayase, Justin, et al.
Publicado: (2017)

How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology – model-based case study
por: Wiśniowska, Barbara, et al.
Publicado: (2021)

On-chip spatiotemporal electrophysiological analysis of human stem cell derived cardiomyocytes enables quantitative assessment of proarrhythmia in drug development
por: Asahi, Yumiko, et al.
Publicado: (2018)

Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery
por: Friedman, Lauren G, et al.
Publicado: (2014)

Effect of hydroxychloroquine on proarrhythmia risk assessment using human iPSC-derived cardiomyocytes
por: Yanagida, Shota, et al.
Publicado: (2021)

CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia
por: Hegyi, Bence, et al.
Publicado: (2021)

The influence of errors in genetic covariances on the efficiency of a cow index
por: Zarnecki, A
Publicado: (1976)

Cannot write session to /tmp/vufind_sessions/sess_29hpl006nb3b0q62lehrj77f9u